Clinician's primer for soft tissue sarcomas: Nuances of histologic subtypes

IF 5.1 2区 医学 Q1 ONCOLOGY Cancer Pub Date : 2025-02-21 DOI:10.1002/cncr.35772
Amy J. Wisdom MD, PhD, Chandrajit P. Raut MD, MS, Candace L. Haddox MD, Jason L. Hornick MD, PhD, Jyothi P. Jagannathan MD, Corrie A. Painter PhD, Elizabeth H. Baldini MD, MPH
{"title":"Clinician's primer for soft tissue sarcomas: Nuances of histologic subtypes","authors":"Amy J. Wisdom MD, PhD,&nbsp;Chandrajit P. Raut MD, MS,&nbsp;Candace L. Haddox MD,&nbsp;Jason L. Hornick MD, PhD,&nbsp;Jyothi P. Jagannathan MD,&nbsp;Corrie A. Painter PhD,&nbsp;Elizabeth H. Baldini MD, MPH","doi":"10.1002/cncr.35772","DOIUrl":null,"url":null,"abstract":"<p>Soft tissue sarcomas are a rare group of mesenchymal malignancies, with greater than 100 histologic subtypes. Advancements in understanding these subtypes has enabled histology-tailored management. This primer describes the workup and management of generalized soft tissue sarcomas of the extremity, trunk, and retroperitoneum while also highlighting the unique attributes of many subtypes. The subtypes chosen for review include those that are most common as well as those demonstrating unique behaviors or targets for management. The focus is on initial management of localized disease; however, for situations in which novel systemic agents have been discovered, the treatment of metastatic disease is discussed. This report is a reference to be used in addition to other comprehensive reviews, such as guidelines from the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the American Society for Radiation Oncology. It is not a substitute for referral to an expert sarcoma center for critical pathology review and management by an experienced team. Importantly, patients who are treated at expert sarcoma centers have better outcomes than those who are not.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 5","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35772","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Soft tissue sarcomas are a rare group of mesenchymal malignancies, with greater than 100 histologic subtypes. Advancements in understanding these subtypes has enabled histology-tailored management. This primer describes the workup and management of generalized soft tissue sarcomas of the extremity, trunk, and retroperitoneum while also highlighting the unique attributes of many subtypes. The subtypes chosen for review include those that are most common as well as those demonstrating unique behaviors or targets for management. The focus is on initial management of localized disease; however, for situations in which novel systemic agents have been discovered, the treatment of metastatic disease is discussed. This report is a reference to be used in addition to other comprehensive reviews, such as guidelines from the National Comprehensive Cancer Network, the European Society for Medical Oncology, and the American Society for Radiation Oncology. It is not a substitute for referral to an expert sarcoma center for critical pathology review and management by an experienced team. Importantly, patients who are treated at expert sarcoma centers have better outcomes than those who are not.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
软组织肉瘤的临床引物:组织学亚型的细微差别
软组织肉瘤是一组罕见的间充质恶性肿瘤,有超过100个组织学亚型。对这些亚型的理解的进步使组织定制化管理成为可能。本引物描述了四肢、躯干和腹膜后广泛性软组织肉瘤的检查和治疗,同时也强调了许多亚型的独特属性。选择用于审查的子类型包括那些最常见的,以及那些为管理展示独特行为或目标的。重点是局部疾病的初步管理;然而,在新的全身性药物被发现的情况下,转移性疾病的治疗被讨论。除了其他综合评价,如国家综合癌症网络、欧洲肿瘤医学学会和美国放射肿瘤学会的指导方针外,本报告还可作为参考。它不能代替由经验丰富的团队转诊到专家肉瘤中心进行重要的病理检查和管理。重要的是,在专家肉瘤中心接受治疗的患者比没有接受治疗的患者有更好的结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
期刊最新文献
The myeloma divide: How sex and age shape disease characteristics. The impact of the patient macroenvironment on molecular subgroups in endometrial cancer. Risks of thrombosis and hemorrhage in concurrent use of anticoagulants and potential interacting prostate cancer agents. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Correction to "Transmission ratio distortion of germline TP53 variants in Li-Fraumeni syndrome families".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1